Join us for an Xtalks webinar:

As neurodegenerative diseases such as Alzheimer’s and Parkinson’s continue to rise, researchers are turning to innovative biomarker strategies, digital health technologies, and precision medicine approaches to improve disease detection, optimize clinical trial design, and accelerate therapeutic development.

Hear from leading experts as they explore how biological, imaging, digital, and wearable biomarkers are transforming neurodegeneration research, enabling more efficient trials, improved patient selection, and the development of next-generation therapies.

What You Will Learn
  • Discover how biological, digital, imaging, and wearable biomarkers are transforming neurodegenerative disease research and enabling earlier, more precise disease detection
  • Learn how biomarker-driven approaches can improve patient selection, optimize clinical trial design, and support personalized therapeutic development
  • Explore real-world applications of digital health technologies and wearable devices for monitoring disease progression and treatment response
  • Gain practical insights into the opportunities, challenges, and future trends shaping data-driven CNS drug development and precision medicine
Who Should Attend

This webinar will appeal to clinicians, researchers, and industry professionals involved in neurodegenerative disease research, CNS research, and clinical and drug development.

Speakers

Bob Dagher, MD | Chief Medical Officer | Clinilabs

Robin Wolz, PhD | Chief Scientific Officer and Chief Medical Officer | IXICO

Brian Murphy, PhD | Co-Founder and Chief Scientific Officer | Cumulus Neuro

Dr. Bill Bryom | VP, Product Intelligence and Positioning, Principal, eCOA Science, Senior Visiting Professor, Nottingham Trent University | Signant Health

Event Information

When: Monday, October 5, 2026

Time: 12pm EDT (NA) / 5pm BST (UK) / 6pm CEST (EU-Central)

Duration: 60 minutes | Live & QA

Back to Events

When you need to get your product to the people who need it most, your pathway to CNS approval starts with Clinilabs.

Get in Touch